SCIGEN LIMITED (SIE.AX)
From ValueWiki
Business Description from asx.com.au: Involved in the development, marketing and sales of a portfolio of bio-pharmaceutical products. These products include vaccines, which are designed to prevent disease and therapeutic bio-pharmaceuticals, which are intended to cure, suppress or minimize disease progression.[1]
|
|
Company Analysis
You can add your own information here - just click the blue edit tab. Or view examples at the Start a new article page.
The edit window has shortcut and help links if you need them.[2] Be bold!
News Feed
Leadership
- SCIGEN LIMITED Executive Information
- SCIGEN LIMITED Directors / Senior Management[1]
Mr Paul Freiman (Chairman) Mr Saul Mashaal (CEO, Vice Chairman) Ms Jenny Low (CFO) Mr Martin Cooper (CFO) Mr Kenneth Gross (Non Exec. Director) Mr Adam Wilezega (Non Exec. Director) Mr Ryszard Krauze (Non Exec. Director) Dr Marian Gorecki (Non Exec. Director)
Risks
This section needs content! Click the blue edit link (to the right) to contribute.
Research Links
- SCIGEN LIMITED Profile
- SCIGEN LIMITED Fundamentals
- SCIGEN LIMITED Technical Analysis
- SCIGEN LIMITED Contact Information[1]
- Website: http://www.scigen.com.au
- Address: Level 7 , 2 Bligh Street , SYDNEY , NSW, AUSTRALIA, 2000
- Phone: (02) 9234 1700
- Fax: (02) 9234 1777
- Share Registry: COMPUTERSHARE INVESTOR SERVICES PTY LIMITED LEVEL 5 , 115 GRENFELL STREET , ADELAIDE , SA, AUSTRALIA, 5000
- Share Registry Phone: 1300 787 373 (BKR ONLY)
- SCIGEN LIMITED Message Boards
Notes
- ↑ 1.0 1.1 1.2 http://www.asx.com.au/asx/research/CompanyInfoSearchResults.jsp?searchBy=asxCode&allinfo=on&asxCode=SIE ASX.com.au
- ↑ This is a sample reference.
